Rheumatoid Arthritis - Market Insight, Epidemiology, and Market Forecast - 2036

Rheumatoid Arthritis Market Insights and Trends

• Currently, nearly 1 in 4 Americans approximately 60 million individuals are affected by arthritis, with a substantial proportion experiencing chronic pain that significantly impairs daily functioning, highlighting a considerable clinical and socioeconomic burden and reinforcing the need for sustained investment in research and more effective management strategies.
• First-degree relatives of individuals with rheumatoid arthritis have a 2-3-fold increased risk, while the relatively low concordance in monozygotic twins (~15-20%) highlights a substantial role of non-genetic factors; the consistent global prevalence further suggests that ubiquitous environmental triggers, potentially infectious agents, may contribute to disease etiology.
• The primary goals of rheumatoid arthritis treatment are to suppress inflammation, achieve remission, alleviate symptoms, prevent joint and organ damage, and improve overall function and long-term outcomes; this is primarily achieved with disease-modifying antirheumatic drugs (DMARDs), which slow disease progression and limit structural damage, while biologic DMARDs are used in inadequate responders to target specific immune pathways and further reduce disease activity and joint deterioration.
• Drugs approved for the treatment of rheumatoid arthritis include upadacitinib (AbbVie), barticinib (Eli Lilly and Company), sarilumab (Regeneron/Sanofi), tofacitinib (Pfizer), among others.
• Emerging therapies like AZD1163 and AZD6912 (AstraZeneca), ocadusertib (Eli Lilly and Company), R-2487 (Rise Therapeutics), MYMD-1 (TNF Pharmaceuticals), and others are being developed for safe and efficacious treatment options.
• There's no cure for rheumatoid arthritis. However, early diagnosis and appropriate treatment enables many people with the condition to have periods of months or even years between flares. This can help them to lead full lives and continue regular employment.

Rheumatoid Arthritis Market Size and Forecast in the 7MM

• 2025 Rheumatoid Arthritis Market Size: ~USD 31.00 billion
• Rheumatoid Arthritis Growth Rate (2026-2036): ~2% CAGR

The “Rheumatoid Arthritis - Market Insights, Epidemiology, and Market Forecast - 2036” report delivers an in-depth understanding of Rheumatoid arthritis, historical and forecasted epidemiology as well as rheumatoid arthritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The rheumatoid arthritis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM rheumatoid arthritis market size from 2022 to 2036. The report also covers current rheumatoid arthritis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

Key Factors Driving the Rheumatoid Arthritis Market

Rising Global Disease Burden

Rheumatoid arthritis imposes a significant and growing global healthcare burden as a chronic autoimmune disease characterized by persistent joint inflammation, pain, disability, and reduced quality of life. Increasing prevalence, aging populations, and improved diagnosis contribute to higher disease burden and long-term healthcare utilization, driving sustained demand for effective disease-modifying therapies.

Rising Opportunities in Rheumatoid Arthritis

The rheumatoid arthritis treatment landscape is evolving with advancements in targeted biologics, Janus kinase (JAK) inhibitors, and personalized therapeutic approaches, along with improved early diagnosis and treat-to-target strategies. Rising awareness, supportive clinical guidelines, and increasing research investments are further accelerating innovation and expanding treatment opportunities.

Rheumatoid Arthritis Understanding and Treatment Algorithm

Rheumatoid Arthritis Overview and Diagnosis

Rheumatoid arthritis is a chronic systemic inflammatory autoimmune disease of unknown cause, typically presenting as bilateral, symmetric polyarthritis of the hands and feet, though any synovial joint and extra-articular organs such as the skin, heart, lungs, and eyes may be involved. It is believed to arise in genetically predisposed individuals (e.g., HLA-DR4/DR1 carriers) following environmental triggers like smoking or infection, leading to an autoimmune response. Although no single test is definitive, diagnosis relies on clinical evaluation and supportive findings such as inflammatory markers (ESR, CRP) and autoantibodies including rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), with imaging (X-ray, ultrasound, MRI) used to assess joint damage and disease progression.

Rheumatoid Arthritis Treatment Landscape

Optimal management of rheumatoid arthritis involves a comprehensive approach combining pharmacologic and nonpharmacologic strategies, including exercise, physical therapy, lifestyle modifications, and patient engagement to improve outcomes and adherence. Drug therapy includes nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs), with early initiation of DMARDs as the standard of care to slow disease progression and induce remission. A treat-to-target approach is recommended, aiming for low disease activity or remission using validated measures (e.g., CDAI, DAS28, SDAI), with treatment adjustments such as optimizing methotrexate use or adding/switching to biologic or targeted synthetic DMARDs if goals are not achieved. In advanced or refractory cases, surgical interventions like synovectomy, tendon repair, or joint replacement may be required.

Rheumatoid Arthritis Unmet Needs

The section “unmet needs of rheumatoid arthritis” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

• Inadequate treatment response
• Lack of predictive biomarkers
• Safety and tolerability concerns
• Delayed diagnosis and disease heterogeneity, and others…..

Rheumatoid Arthritis Epidemiology

Key Findings from Rheumatoid Arthritis Epidemiological Analysis and Forecast

• As per Xu et al. (2021), in the US, approximately 1.3 million adults suffer from rheumatoid arthritis, representing 0.6% to 1% of the adult population.
• As per Stanciu et al. (2022), the estimated prevalence for rheumatoid arthritis in the adults is around 0.81%, with a higher prevalence for women (1.16%) than for men (0.44%) in the UK.
• According to the World Health Organization (2023), about 70% of people living with rheumatoid arthritis are women, and 55% are older than 55 years of age.
• As per Jinno et al. (2019) and Bergstra et al. (2018), the targeted therapies usage varies from 18% to 50% in Japan, which is similar to the usage of targeted therapies in the US.
• Rheumatoid arthritis mortality has decreased globally over the past three decades. Global age standardized prevalence rate have increased over the same period, and the number of cases is projected to continue to increase.
• While rheumatoid arthritis is a systemic autoimmune disease that affects multiple body systems, the joints of hands, wrists, feet, ankles, knees, shoulders and elbows are most often affected.

Rheumatoid Arthritis Drug Analysis & Competitive Landscape

The rheumatoid arthritis drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I/II-II clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the rheumatoid arthritis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the rheumatoid arthritis therapeutics market.

Approved Therapies for Rheumatoid Arthritis

Upadacitinib (RINVOQ): Abbvie

Upadacitinib, an AbbVie product is a prescription medicine used to treat adults with moderate to severe rheumatoid arthritis in whom methotrexate did not work well or could not be tolerated. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.

Upadacitinib obtained regulatory approval across key global markets, including the United States and European Union in 2019, followed by approval in Japan in 2020.

Barticinib (OLUMIANT): Eli Lilly and Company/Incyte

Barticinib by Eli Lilly and Company/Incyte is a JAK inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Barticinib obtained regulatory approval for the treatment of rheumatoid arthritis across key global markets, including the European Union and Japan in 2017, followed by approval in the United States in 2018.

Rheumatoid Arthritis Pipeline Analysis

TAS5315: Taiho Pharmaceutical

TAS5315 is a novel, highly selective inhibitor of BTK. Targeting BTK may be efficacious against inflammation and bone erosion through direct regulation of activation of effector cells such as B cells, macrophages, and osteoclasts in rheumatoid arthritis.

The company is evaluating a Phase II trial to evaluate safety and efficacy of TAS5315 in combination with methotrexate in participants with rheumatoid arthritis with inadequate response to methotrexate in Japan.

R-2487: Rise Therapeutics

R-2487 is a targeted oral immunotherapy designed to induce T regulatory cells and restore immune balance in autoimmune diseases, including rheumatoid arthritis. Its unique mechanism of action activates specific immune pathways to reset regulatory deficiencies and reduce inflammatory cytokines that drive autoimmune pathology. It is currently evaluating in Phase I of clinical trials.

Rheumatoid Arthritis Key Players, Market Leaders and Emerging Companies

• Rise Therapeutics
• Taiho Pharmaceutical
• Abbvie
• Eli Lilly and Company/Incyte
• AstraZeneca, and others.

Rheumatoid Arthritis Drug Updates

• In January 2025, Rise therapeutics, announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials. Both studies will now initiate the planned dose expansion stages to enroll additional patients at fixed doses.
• According to the AstraZeneca FY clinical trial appendix 2025, AZD1163 (NCT06103877) has advanced to Phase II, while AZD6912 (NCT06115967) remains in Phase I; data for both programs are anticipated after 2026.

Rheumatoid Arthritis Market Outlook

Management of Rheumatoid arthritis has evolved significantly, with improved outcomes driven by early, aggressive intervention and treat-to-target strategies. While NSAIDs provide short-term symptomatic relief, disease-modifying antirheumatic drugs (DMARDs) are central to therapy, targeting inflammation and preventing structural damage, increasingly used in early and combination regimens to optimize disease control. Supportive therapies enhance functional outcomes, whereas surgery is now largely reserved for advanced, refractory cases, reflecting a shift toward proactive disease management and long-term remission.

In the management of Rheumatoid arthritis, Methotrexate remains the first-line DMARD due to its balanced profile of efficacy, relatively rapid onset, tolerability, and cost-effectiveness. For patients with inadequate response, treatment escalation involves biologic DMARDs targeting key inflammatory pathways, including TNF-α inhibitors such as HUMIRA, CIMZIA, and SIMPONI, as well as interleukin inhibitors like ACTEMRA and KEVZARA, alongside agents targeting T-cell co-stimulation or B-cell depletion. Additionally, Kineret is used in refractory cases. More recently, targeted synthetic DMARDs such as JAK inhibitors including XELJANZ and Barticinib have expanded the treatment paradigm by offering effective oral options, particularly for patients intolerant or unresponsive to conventional or biologic therapies..


Drug Class/Insights into Leading Emerging and Marketed Therapies in Rheumatoid Arthritis (2026-2036 Forecast)

Small molecules: Small-molecule therapies for rheumatoid arthritis target key inflammatory and immune pathways involved in disease progression. These agents, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and Janus kinase (JAK) inhibitors, work by reducing inflammation, modulating immune responses, and alleviating symptoms, thereby helping control disease activity and improve patient outcomes.

Rheumatoid Arthritis Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2022-2036. The landscape of rheumatoid arthritis treatment has experienced a profound transformation with the uptake of novel drugs. These innovative therapies are redefining standards of care. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of physicians, professionals, and the entire healthcare community in their tireless pursuit of advancing disease care. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.

Market Access and Reimbursement of Approved therapies in Rheumatoid Arthritis

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Rheumatoid Arthritis Therapies Price Scenario & Trends

Pricing and analogue assessment of rheumatoid arthritis therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Rheumatoid Arthritis

To keep up with rheumatoid arthritis market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the rheumatoid arthritis emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Influenza and others.

The analysts connected with 15+ KOLs to gather insights at country level. Centers such as the Medicine at Harvard Medical School in the US, Oxford University in the UK, University of California, San Francisco, and University of Heidelberg in Germany, etc. were contacted.Their opinion helps understand and validate current and emerging rheumatoid arthritis therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in rheumatoid arthritis.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of rheumatoid arthritis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of rheumatoid arthritis, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the rheumatoid arthritis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM rheumatoid arthritis market.

Report Insights

• Rheumatoid Arthritis Patient Population Forecast
• Rheumatoid Arthritis Therapeutics Market Size
• Rheumatoid Arthritis Pipeline Analysis
• Rheumatoid Arthritis Market Size and Trends
• Rheumatoid Arthritis Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Rheumatoid Arthritis Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Rheumatoid Arthritis Treatment Addressable Market (TAM)
• Rheumatoid ArthritisCompetitve Landscape
• Rheumatoid Arthritis Major Companies Insights
• Rheumatoid Arthritis Price Trends and Analogue Assessment
• Rheumatoid ArthritisTherapies Drug Adoption/Uptake
• Rheumatoid ArthritisTherapies Peak Patient Share Analysis

Report Assessment

• Rheumatoid Arthritis Current Treatment Practices
• Rheumatoid Arthritis Unmet Needs
• Rheumatoid Arthritis Clinical Development Analysis
• Rheumatoid Arthritis Emerging Drugs Product Profiles
• Rheumatoid Arthritis Market attractiveness
• Rheumatoid Arthritis Qualitative Analysis (SWOT and conjoint analysis)

FAQs

Market Insights

• What was the rheumatoid arthritis market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of rheumatoid arthritis?
• What are the disease risks, burdens, and unmet needs of rheumatoid arthritis ? What will be the growth opportunities across the 7MM concerning the patient population with rheumatoid arthritis?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of rheumatoid arthritis? What are the current guidelines for treating rheumatoid arthritis in the US, Europe, and Japan?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the rheumatoid arthritis market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

This product will be delivered within 5-7 business days.